Download PDF
CC BY-NC-ND 4.0 · Journal of Child Science 2018; 08(01): e116-e123
DOI: 10.1055/s-0038-1667349
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Anesthesia Risk and the Mucopolysaccharidoses: A Challenging and Changing Landscape

Robert W. M. Walker
1   Department of Pediatric Anesthesia, Royal Manchester Children's Hospital, Manchester, United Kingdom
,
James Garbarino
2   Department of Anesthesia, Royal Manchester Children's Hospital, Manchester, United Kingdom
› Author Affiliations
Further Information

Publication History

13 October 2017

18 April 2018

Publication Date:
03 October 2018 (online)

   Permissions and Reprints

Abstract

The mucopolysaccharidoses (MPS) are well known to present a high risk of anesthesia. Predominantly, this risk is not only related to upper airway issues but also to multilevel airway obstruction, respiratory morbidity, and cardiac issues. Before disease-specific treatment became available, the management of the untreated patients with MPS was regarded as the worst airway problem in pediatric anesthetic practice. The last 20 to 30 years have seen great advances in the treatment of the different types of MPS with hematopoietic stem cell transplantation (HSCT) being offered to children with MPS I Hurler sundrome since the 1980s, and more recently enzyme replacement therapy (ERT) becoming available for many MPS subtypes.

These treatments have undoubtedly affected the relative risk involved with an anesthetic. HSCT improves markedly the upper airway and cardiac myocardial function and there is evidence that airway management is much more straightforward. ERT, on the other hand, improves obstructive sleep apnea and exercise tolerance, but the overall effect on the risk of anesthesia is less obvious and airway complications during anesthesia remain at a high level. The impact of improved anesthetic management in the same time frame is borne out by a reduced failed intubation rate in the literature.

The management of the MPS patients necessitates a multidisciplinary approach presently widely practiced in pediatric centers, but successful modes of therapy increasing their life span have pushed many of the extreme anesthetic challenges into adult practice where most anesthetists will be unfamiliar with the problem. This is a problem that needs to be addressed, and solutions to this issue could be collaborative working between pediatric and adult practitioners or an international network of experts available for advice.

Keywords

anesthesia - mucopolysaccharidosis - airway management
 

  • References

  • 1 Smith RM. Anesthesia for Infants and Children. 4th ed. St. Louis, MO: CV Mosby; 1980: 533-536
    Google Scholar
  • 2 DeLange C, Gerlings PG, DeKleyn A, Lettinga TW. Some remarks on gargoylism. Acta Paediatr 1943; 31: 398-410
    PubMedGoogle Scholar
  • 3 Hopkins R, Watson JA, Jones JH, Walker M. Two cases of Hunter's syndrome--the anaesthetic and operative difficulties in oral surgery. Br J Oral Surg 1973; 10 (03) 286-299
    PubMedGoogle Scholar
  • 4 Herrick IA, Rhine EJ. The mucopolysaccharidoses and anaesthesia: a report of clinical experience. Can J Anaesth 1988; 35 (01) 67-73
    CrossrefPubMedGoogle Scholar
  • 5 Kempthorne PM, Brown TCK. Anaesthesia and the mucopolysaccharidoses: a survey of techniques and problems. Anaesth Intensive Care 1983; 11 (03) 203-207
    PubMedGoogle Scholar
  • 6 Sjøgren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand 1987; 31 (03) 214-218
    CrossrefPubMedGoogle Scholar
  • 7 Baines D, Keneally J. Anaesthetic implications of the mucopolysaccharidoses: a fifteen-year experience in a children's hospital. Anaesth Intensive Care 1983; 11 (03) 198-202
    PubMedGoogle Scholar
  • 8 Belani KG, Krivit W, Carpenter BL. , et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings. J Pediatr Surg 1993; 28 (03) 403-408 , discussion 408–410
    CrossrefPubMedGoogle Scholar
  • 9 Walker RW, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia 1994; 49 (12) 1078-1084
    CrossrefPubMedGoogle Scholar
  • 10 Moores C, Rogers JG, McKenzie IM, Brown TC. Anaesthesia for children with mucopolysaccharidoses. Anaesth Intensive Care 1996; 24 (04) 459-463
    PubMedGoogle Scholar
  • 11 Arn P, Whitley C, Wraith JE. , et al. High rate of postoperative mortality in patients with mucopolysaccharidosis I: findings from the MPS I Registry. J Pediatr Surg 2012; 47 (03) 477-484
    CrossrefPubMedGoogle Scholar
  • 12 Fecho K, Lunney AT, Boysen PG, Rock P, Norfleet EA. Postoperative mortality after inpatient surgery: incidence and risk factors. Ther Clin Risk Manag 2008; 4 (04) 681-688
    CrossrefPubMedGoogle Scholar
  • 13 Walker R, Belani KG, Braunlin EA. , et al. Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36 (02) 211-219
    CrossrefPubMedGoogle Scholar
  • 14 Mendelsohn NJ, Harmatz P, Bodamer O. , et al; Hunter Outcome Survey Investigators. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med 2010; 12 (12) 816-822
    PubMedGoogle Scholar
  • 15 Berger KI, Fagondes SC, Giugliani R. , et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis 2013; 36 (02) 201-210
    CrossrefPubMedGoogle Scholar
  • 16 Leboulanger N, Louis B, Vialle R, Heron B, Fauroux B. Analysis of the upper airway by the acoustic reflection method in children with mucopolysaccharidosis. Pediatr Pulmonol 2011; 46 (06) 587-594
    CrossrefPubMedGoogle Scholar
  • 17 Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2005; 69 (05) 589-595
    CrossrefPubMedGoogle Scholar
  • 18 Morimoto N, Kitamura M, Kosuga M, Okuyama T. CT and endoscopic evaluation of larynx and trachea in mucopolysaccharidoses. Mol Genet Metab 2014; 112 (02) 154-159
    CrossrefPubMedGoogle Scholar
  • 19 Kamin W. Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr 2008; 97 (457) 57-60
    CrossrefPubMedGoogle Scholar
  • 20 Malik V, Nichani J, Rothera MP. , et al. Tracheostomy in mucopolysaccharidosis type II (Hunter's syndrome). Int J Pediatr Otorhinolaryngol 2013; 77 (07) 1204-1208
    CrossrefPubMedGoogle Scholar
  • 21 Walker PP, Rose E, Williams JG. Upper airways abnormalities and tracheal problems in Morquio's disease. Thorax 2003; 58 (05) 458-459
    CrossrefPubMedGoogle Scholar
  • 22 Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jüngst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 1995; 154 (02) 98-101
    CrossrefPubMedGoogle Scholar
  • 23 Kimball TR. Pediatric stress echocardiography. Pediatr Cardiol 2002; 23 (03) 347-357
    CrossrefPubMedGoogle Scholar
  • 24 Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 2007; 30 (05) 820
    CrossrefPubMedGoogle Scholar
  • 25 Dilber E, Celiker A, Karagöz T, Kalkanoğlu HS. Permanent transfemoral pacemaker implantation in a child with Maroteaux Lamy syndrome. Pacing Clin Electrophysiol 2002; 25 (12) 1784-1785
    CrossrefPubMedGoogle Scholar
  • 26 Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br 1996; 78 (06) 938-944
    CrossrefPubMedGoogle Scholar
  • 27 Thorne JA, Javadpour M, Hughes DG, Wraith E, Cowie RA. Craniovertebral abnormalities in type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 2001; 48 (04) 849-852 , discussion 852–853
    PubMedGoogle Scholar
  • 28 Kirkpatrick K, Ellwood J, Walker RW. Mucopolysaccharidosis type I (Hurler syndrome) and anesthesia: the impact of bone marrow transplantation, enzyme replacement therapy, and fiberoptic intubation on airway management. Paediatr Anaesth 2012; 22 (08) 745-751
    CrossrefPubMedGoogle Scholar
  • 29 Muenzer J, Wraith JE, Clarke LA. ; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009; 123 (01) 19-29
    CrossrefPubMedGoogle Scholar
  • 30 de Ru MH, Boelens JJ, Das AM. , et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 2011; 6: 55
    CrossrefPubMedGoogle Scholar
  • 31 Boelens JJ, Aldenhoven M, Purtill D. , et al; Eurocord; Inborn Errors Working Party of European Blood and Marrow Transplant group; Duke University Blood and Marrow Transplantation Program; Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013; 121 (19) 3981-3987
    CrossrefPubMedGoogle Scholar
  • 32 Aldenhoven M, Wynn RF, Orchard PJ. , et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015; 125 (13) 2164-2172
    CrossrefPubMedGoogle Scholar
  • 33 Frawley G, Fuenzalida D, Donath S, Yaplito-Lee J, Peters H. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses. Paediatr Anaesth 2012; 22 (08) 737-744
    CrossrefPubMedGoogle Scholar
  • 34 Muenzer J, Beck M, Giugliani R. , et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13 (02) 102-109
    PubMedGoogle Scholar
  • 35 McGill JJ, Inwood AC, Coman DJ. , et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet 2010; 77 (05) 492-498
    CrossrefPubMedGoogle Scholar
  • 36 Parini R, Deodato F, Di Rocco M. , et al. Open issues in mucopolysaccharidosis type I-Hurler. Orphanet J Rare Dis 2017; 12 (01) 112
    CrossrefPubMedGoogle Scholar
  • 37 Hack HA, Walker R, Gardiner P. Anaesthetic implications of the changing management of patients with mucopolysaccharidosis. Anaesth Intensive Care 2016; 44 (06) 660-668
    CrossrefPubMedGoogle Scholar
  • 38 Wraith JE, Beck M, Lane R. , et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007; 120 (01) e37-e46
    CrossrefPubMedGoogle Scholar
  • 39 Brands MM, Frohn-Mulder IM, Hagemans ML. , et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis 2013; 36 (02) 227-234
    CrossrefPubMedGoogle Scholar
  • 40 Fesslová V, Corti P, Sersale G. , et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009; 19 (02) 170-178
    CrossrefPubMedGoogle Scholar
  • 41 Hendriksz CJ, Al-Jawad M, Berger KI. , et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis 2013; 36 (02) 309-322
    CrossrefPubMedGoogle Scholar
  • 42 Clarke LA, Wraith JE, Beck M. , et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123 (01) 229-240
    CrossrefPubMedGoogle Scholar
  • 43 Harmatz P, Whitley CB, Waber L. , et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144 (05) 574-580
    CrossrefPubMedGoogle Scholar
  • 44 Harmatz P, Yu ZF, Giugliani R. , et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 2010; 33 (01) 51-60
    PubMedGoogle Scholar
  • 45 Pal AR, Langereis EJ, Saif MA. , et al. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet J Rare Dis 2015; 10: 42
    CrossrefPubMedGoogle Scholar
  • 46 Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2017; 40 (06) 867-874
    CrossrefPubMedGoogle Scholar
  • 47 Osthaus WA, Harendza T, Witt LH. , et al. Paediatric airway management in mucopolysaccharidosis 1: a retrospective case review. Eur J Anaesthesiol 2012; 29 (04) 204-207
    PubMedGoogle Scholar
  • 48 Megens JH, de Wit M, van Hasselt PM, Boelens JJ, van der Werff DB, de Graaff JC. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. Paediatr Anaesth 2014; 24 (05) 521-527
    CrossrefPubMedGoogle Scholar
  • 49 Theroux MC, Nerker T, Ditro C, Mackenzie WG. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth 2012; 22 (09) 901-907
    CrossrefPubMedGoogle Scholar
  • 50 Walker RW, Colovic V, Robinson DN, Dearlove OR. Postobstructive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paediatr Anaesth 2003; 13 (05) 441-447
    CrossrefPubMedGoogle Scholar
  • 51 Walker RW, Allen DL, Rothera MR. A fibreoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. Paediatr Anaesth 1997; 7 (05) 421-426
    CrossrefPubMedGoogle Scholar